We started ETX Pharma to develop safe drugs for patients with serious gastrointestinal diseases. Our guiding principles are to develop and commercialize drugs that treat the underlying cause of disease with patient friendly oral formulations.
ETX was founded in 2014 by a seasoned team of entrepreneurs and leading medical experts to provide novel drugs to patients suffering with serious gastrointestinal diseases whose only currently available therapies are often dangerous or ineffective drugs
Meet the Team
Please meet the key people building ETX Pharma, Inc into
a global leaderin the treatment of major gastrointestinal diseases
Dr Craig M Liddell
President & CEO
Dr Liddell has over two decades in the biotechnology industry with several successful exits in Genomics, Cardiovascular disease, Oncology and Gastrointestinal Disease. He was a Senior Executive for an IPO in 2001 after a successful academic career as Senior Editor and reviewer for several high profile journals and NIH and NSF grants programs. He actively volunteers on several community organizations in Northern Virginia.
Dr Christine Copple
Chief Operating Officer
Dr. Copple has three decades as a corporate officer, in enterprises from oncology to neural stem cells, responsible for funding, business development, operations, build out, cGMP build/design, regulatory, international marketing & sales and R&D. She also ran the American Society of Microbiology seed venture fund. A founder of 2 public companies she currently serves on the Board of the Washington D.C. ArchAngels and Chairs their Bio-Life-Science Caucus.
Dr Ralph Scannell
Dr. Scannell has more than 30 years of experience in the pharmaceutical/biotechnology industry where he held several leadership roles in drug discovery and development in multiple therapeutic areas. He was responsible for delivering several drug candidates into preclinical development and three drugs into clinical development.
If you are interested in ETX Pharma, Inc and wish to receive more information please contact us...